Kiniksa Pharmaceuticals (NASDAQ:KNSA) Target Raised by Wedbush to $38.00

0
23
highrise buildings at Wall Street financial district in New York City from below.

Kiniksa Pharmaceuticals stock has undergone multiple analysts rating changes in the recent past.  Kiniksa Pharmaceuticals stock Target Raised by   Wedbush on 6/29/2020. In a note to investors, the firm issued a new target price of $38.00. The analysts previously had $30.00 target price. Wedbush’s price target would indicate a potential upside of 37.73% from the stock’s previous close.

Shares of Kiniksa Pharmaceuticals traded up $2.97 on Monday, reaching $26.00. 1064533 shares of the stock traded hands, compared to its average volume of 258557. Shares of were trading at $26.00 on Monday. The firm’s 50 day moving average is $21.72 and its 200 day moving average is 14.62.Kiniksa Pharmaceuticals  has a 12 month low of $25.44 and a 12 month high of $28.67. While on yearly highs and lows, Kiniksa Pharmaceuticals today has traded high as $28.67 and has touched $25.44 on the downward trend.

Kiniksa Pharmaceuticals Earnings and What to expect: 

Kiniksa Pharmaceuticals last announced its earnings results on April 28th, 2020. The reported ($0.48) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.15. Kiniksa Pharmaceuticals has generated ($2.99) earnings per share over the last year. Kiniksa Pharmaceuticals has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Monday, August 10th, 2020 based off prior year’s report dates.

Latest Insiders Trading and Volume : 

  • Insider Ownership Percentage: 59.92%
  • On 6/10/2020 EVP Thomas W Beetham Sell 13,752 at average share price of $25.07 which equates to $344,762.64 in money value.
  • On 4/20/2020 EVP Thomas W Beetham Sell 47,423 at average price of  $19.06 with total value of : Not Data Available
  • On 3/6/2020 CEO Sanj K Patel Sell 33,115 at average price of  $20.00 with total value of : $662,300.00
  • See More Analyst Rating at: RATING

Other Analyst’s rating for Kiniksa Pharmaceuticals

  • 4/29/2020 – Kiniksa Pharmaceuticals was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating. ()
  • 4/23/2020 – Kiniksa Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $23.00 price target on the stock. ()
  • 4/11/2020 – Kiniksa Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. ()
  • 4/9/2020 – Kiniksa Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $19.00 price target on the stock. ()
  • See More Analyst Rating at: RATING

Other rating updates by Wedbush: 

  • 6/25/2020 – Accenture had its “outperform” rating re-affirmed by analysts at Wedbush. ()
  • 6/26/2020 – Ascendis Pharma A/S is now covered by analysts at Wedbush. They set a “buy” rating and a $188.00 price target on the stock. ()
  • 6/26/2020 – Varonis Systems had its price target raised by analysts at Wedbush from $88.00 to $110.00. ()
  • 6/26/2020 – Microsoft had its “buy” rating re-affirmed by analysts at Wedbush. They now have a $220.00 price target on the stock. ()
  • See More Analyst Rating at: RATING

Kiniksa Pharmaceuticals (NASDAQ:KNSA) Moving Average Technical Analysis

5 day Moving Average is $25.06 And 5 day price change is 2.99 (0.1196)  with average volume for 5 day average is 389,831. While technical analysis for average 20 days shows significant difference, 20 day moving average is  23.44 and 20 day price change is 6.43 (0.2981) and average 20 day moving volume is 282,938. 50 day moving average is 21.72  and 50 day price change is 9.62 ( 0.5234)  and with average volume for 50 days is : 284,691. 200 day moving average is 14.62  and 200 day price change is 18.5 (1.9474)  and with average volume for 200 days is : 257,388.

See More Analyst Rating at: RATING